Entering the third year after the COVID-19 outbreak, the situation has worsened for several industries, including in vaccine production. Earlier this year we reported that the Commercial Court at the Central Jakarta District Court registered a lawsuit filed by a Chinese super conglomerate against PT Biotis Prima Agrisindo (PT BPA), who has been widely known as parent of PT Biotis Pharmaceutical Indonesia (PT BPI), the company that produce Indonesian-owned Merah Putih vaccines, seeking for the company to restructure its debt. The lawsuit was withdrawn twice only to be registered again this week.
To subscribe please click here
